InMed Pharmaceuticals Inc. (IMLFF) Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a RD pipeline of medications targeting diseases with high unmet medical needs, today provided an update on its drug development program for the treatment of Epidermolysis Bullosa (“EB”).

The Company has determined that the clinical development path forward with its investigational drug candidate for the treatment of EB, previously referred to as INM-750, will be optimized by transitioning

...read more at https://marijuanastocks.com/imlff-announces-transition-to-a-single-cannabinoid-investigational-drug-candidate-inm-755/

by

Leave a Reply